# CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation

> **NCT00227344** · PHASE4 · TERMINATED · sponsor: **Biosense Webster EMEA** · enrollment: 129 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DEVICE:** RF ablation
- **DRUG:** Antiarrhythmic drugs

## Key facts

- **NCT ID:** NCT00227344
- **Lead sponsor:** Biosense Webster EMEA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2008-10
- **Final completion:** 2009-05
- **Target enrollment:** 129 (ACTUAL)
- **Why stopped:** Study prematurely terminated due to randomization imbalance.
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227344, "CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00227344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*